Oral Delivery of SARS-CoV-2 DNA Vaccines Using Attenuated
Salmonella typhimurium as a Carrier in Rat

Dan Zhu a, Mengyue Mengyue a, Aaodeng Qimuge a, Bilige Bilige a, Tegexi Baiyin a, Temuqile Temuqile a, Shana Chen a, Siqin Borjigen a, Huricha Baigude b, *, and Dezhi Yang a, **

a Pharmaceutical Laboratory, Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, 010065 China
b School of Chemistry and Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia, 010020 China
* e-mail: hbaigude@imu.edu.cn
** e-mail: imudezhi@hotmail.com

Received May 8, 2021; revised September 27, 2021; accepted December 8, 2021

Abstract—The 2019 novel coronavirus disease (COVID-19) is the disease that has been identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the prophylactic treatment of SARS-CoV-2 is still under investigation. The effective delivery of eukaryotic expression plasmids to the immune system’s inductive cells constitutes an essential requirement for generating effective DNA vaccines. Here, we have explored the use of Salmonella typhimurium as vehicles to deliver expression plasmids orally. The attenuated Salmonella phoP was constructed by the one-step gene inactivation method, and plasmid-encoded the spike protein of SARS-CoV-2 was transform into the Salmonella phoP by electroporation. Western blot experiment was used for the detection of SARS-CoV-2 expression on 293T cells. Wistar rats were immunized orally with Salmonella that carried a eukaryotic expression plasmid once a week for three consecutive weeks. The ELISA was performed to measure the SARS-CoV-2 specific IgG at rat’s serum samples. pSARS-CoV-2 can be successfully expression on 293T cells, and all immunized animals generated immunity against the SARS-CoV-2 spike protein, indicating that a Salmonella-based vaccine carrying the Spike gene can elicit SARS-CoV-2-specific secondary immune responses in rats. Oral delivery of SARS-CoV-2 DNA vaccines using attenuated Salmonella typhimurium may help develop a protective vaccine against SARS-CoV-2 infection.

Keywords: SARS-CoV-2, DNA vaccine, oral vaccine, antibody response, Salmonella typhimurium

DOI: 10.3103/S0891416822030107

Novel coronavirus disease-2019 (COVID-19) is a life-threatening contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 8 May 2020, data from the World Health Organization (WHO) has shown that since the first SARS-CoV-2 case emerged in China’s Wuhan city, in November 2019, it has affected over 156,433,646 cases in over 200 countries and devitalized near 3,263,874 lives. There is no specific and compelling medicine or vaccine that has developed against SARS-CoV-2, currently treated with heteropathy or conservative therapeutics [1]. Although the first COVID-19 outbreak was controlled by quarantine in China, more and more case reports in other countries indicated that COVID-19 remains a constant threat. Therefore, it is essential to develop a safe and effective vaccine against SARS-CoV-2. Efforts to create safe and effective SARS-CoV-2 vaccines are underway worldwide [2]. Clinical trials utilizing virus (inactivated or attenuated), viral vector (replicating or non-replicating), nucleic acid (DNA or RNA), and protein-based (protein subunit or virus-like particles) developed across the world [3, 4]. An inactivated SARS-CoV-2 vaccine seems to be the most facile and convenient option, but inactivated vaccines are more expensive than oral vaccines, considering the scale of the vulnerable population worldwide. Therefore, developing a gene-based vaccine may be a more promising choice [5].

The SARS-CoV-2 genome (30 kb in size) encodes a large, non-structural polyprotein (ORF1a/b) that is further proteolytically cleaved to generate 15/16 proteins, four structural proteins and five accessory proteins (ORF3a, ORF6, ORF7, ORF8, and ORF9) [6–8]. Those four structural proteins consist of the spike surface glycoprotein, the membrane protein, the envelope protein, and the nucleocapsid protein, which is essential for SARS-CoV-2 assembly and infection. The spike surface glycoprotein plays a crucial role in its attachment to host cells and can be further cleaved by host proteases into an N-terminal S1 subunit and a membrane-bound C-terminal S2 region [9]. Binding of the S1 subunit to a host receptor (i.e., ACE2 receptor) can destabilize the prefusion trimer, leading to shedding of the S1 subunit and transition of the S2 subunit into a highly stable post-fusion conformation [8]. To engage a host receptor, the receptor-binding
domain (RBD) of the S1 subunit undergoes hinge-like conformational movements, which transiently hide or expose the determinants of receptor binding [8, 10].

DNA vaccination, i.e., immunization with an isolated eukaryotic expression plasmid that encodes the antigen rather than immunization with the antigen itself, has added a new dimension to vaccine research [11]. The tremendous flexibility offered by DNA vaccination includes the possibility of co-expressing immunomodulatory molecules like cytokines, co-stimulatory molecules, or antisense RNA to steer the immune response into the required direction. Besides, antigens can be manipulated by the addition of sequences that target transport to particular cellular compartments or influence their processing, thus improving the efficacy of immunization. Furthermore, DNA vaccines can be applied in ways that favor either systemic or mucosal responses. Therefore, it is foreseeable that appropriate expression plasmids for a wide variety of applications will be developed to allow a rapid testing of potential protective vaccine candidates in suitable animal models and a quick assessment of optimal strategy [12].

A significant drawback of genetic vaccination is its inefficiency, which is inherent in the way that vaccines are currently delivered, and its requirement of relatively large amounts of purified plasmids [13]. Thus, it is mandatory to develop a carrier system that improves efficacy and possibly target the vaccines in vivo in mucosal sites and cells of the immune system. The use of bacteria as vehicles for genetic vaccination is an attractive and straightforward idea derived from many intrinsic properties afforded by these systems. Previous studies reported that viral expression of the full-length S protein or S1 subunit of SARS coronavirus elicits a high titer of neutralizing antibodies in monkey and rat models [5, 14, 15]. In this study, we used a eukaryotic expression encoding S protein of SARS-CoV-2 by attenuated Salmonella carrier and investigated its ability to induce specific antibodies against SARS-CoV-2. Our study demonstrated that specific antibodies against SARS-CoV-2 were elicited in a rat model following the oral administration of SARS-CoV-2-S. This result indicates that our construct could be developed into a safe SARS-CoV-2 vaccine.

Table 1. Primers used in this study*

| Primer No. | Sequence |
|------------|----------|
| P1H1       | cgctagacctttattgttaacacaggaggacaatactgtccttaaaaggtttaacagacagacagcagaaataatggecggcag |
| P2H2       | gcaagcaacgcgcgaaaaatggtctaatccggtgtaggactggctcctgactag |
| RT-phoP-F  | taccgccaccaccctaggg |
| RT-phoP-R  | cgtataggaagagccgg |
| RT-rpoD-F  | agcagtgcacaaataatcgagag |

*All oligonucleotides were purchased from Synbio Technologies.

METHODS

Bacterial Strains, Growth Conditions, and Oligonucleotides

Salmonella enterica serovar Typhimurium (S. typhimurium) strains were derived from the wild-type strain ATCC 14028s (14028). Salmonella was grown at 37°C in Luria-Bertani (LB) broth (Difco). When necessary, antibiotics were added to bacterial cultures at final concentrations of 50 μg/mL for ampicillin (Ap), 20 μg/mL for chloramphenicol (Cm), or 50 μg/mL for kanamycin (Km). E. coli DH5 was used as host for the preparation of plasmid DNA, respectively. Oligonucleotides used in this study are given in Table 1. Salmonella phoP (STM1231) was incubated overnight at 37°C with shaking at maximum 50 rpm until an OD600 of 0.6 was reached, then washed and resuspended in phosphate-buffered saline (PBS) with 30% glycerol for oral administration.

Strain Construction and Transformation of Plasmid into S. typhimurium phoP

Salmonella strain gene deletion was generated as described previously [16]. Deletions of the phoP gene were carried out using primer pairs P1H1 and P2H2, to amplify the kanamycin resistance cassette (KmR) from plasmid pKD4 [16], the PCR products were electroporated into wild-type cells harboring pKD46, and KmR colonies were selected. The integration of the drug-resistant cassette into the chromosome in these mutants was confirmed by colony PCR. The KmR cassette was removed by using pCP20. Electroporation was carried out by mixing 100 μL of resuspended cells with 0.2 μg plasmid DNA. The suspension was transferred into a disposable cuvette (Bio-Rad Laboratory, Richmond, CA) with an 0.2 cm electrode gap and subjected to an electric pulse at 8 ms, 1.5 kv, 600 Ohm and 10 μF using a MicroPulser (Bio-Rad Laboratory, Richmond, CA).

In Vitro Transfection of pSARS-CoV-2-S Plasmid

The pcDNA3.1 (+)-CMV-SARS-CoV-2-S-GFP (pSARS-CoV-2-S) plasmid was purchased from Gene script Co., Ltd. (Nanjing, China) (Fig. 1). Plasmid and DNA isolation/purification kits were purchased from TIANGEN Biotech Co., Ltd. (Beijing, China).
Transfection reagent DoGOX was described in our previous study [17]. 293T cells were propagated in Dulbecco's modified Eagle medium (DMEM) (HyClone, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and maintained in a humidified incubator at 37°C with 5% CO₂. For the in vitro transfection experiment, pcDNA3.1(+)−GFP control and pcDNA3.1(+)−CMV-2019-nCoV-S-GFP were used. Cells (1.5 × 10⁵ cells/well) were seeded into 6-well plates the day before transfection. Cells were transfected with 2 μg/well of DNA complexed to DoGox for 24 h, as previously described [18].

Detection of SARS-CoV-2-S Protein Expression In Vitro

For the western blot detection of SARS-CoV-2-S protein, the cells were washed twice with ice-cold PBS and harvested from the dishes with a cell scraper by adding a WIP lysis buffer. The recovered lysate was incubated for 30 min on ice and centrifuged at 14000 g for 20 min to remove cell debris. The protein concentration of whole-cell lysates was determined by using the BCA Protein Assay kit (Pierce). Protein samples were separated by 8% SDS-PAGE and transferred to PVDF membranes (Amersham), then proteins were monitored with ECL Western blotting substrate (Pierce) after incubation with anti-SARS-CoV-2-S-RBD (Sino Biological, China) or anti-P-actin antibody (Solarbio, China).

SARS-CoV-2-S DNA Immunization Delivered by Attenuated S. typhimurium

A total of 18 female Wistar rats (purchase from Sibeifu Biotechnology Company Limited, China)
were randomly divided into two groups, with nine rats each [19]. The first group was immunized orally with \(1 \times 10^7\) attenuated \(S.\) typhimurium \(phoP\) transformed with pcDNA3.1-GFP in 200 \(\mu L\) of PBS [20]. The second group of rats was given 200 \(\mu L\) of PBS with \(1 \times 10^7\) attenuated \(S.\) typhimurium \(phoP\) transformed with pcDNA3.1(+)-CMV-SARS-CoV-2-S-GFP. All mice were given 200 \(\mu L\) of 10% NaHCO₃ orally to neutralize gastric acids before oral inoculation with bacteria. All groups of the rat were boosted three times with the same vaccine components at two weeks interval. All rats survived and were sacrificed at 28 days post-immunization by breaking of the neck method.

**Enzyme Linked Immunosorbant Assay (ELISA)**

As previously described, the sera were used to test the anti-SARS-CoV-2-S IgG antibodies by enzyme-linked immunosorbent assay (ELISA) [21]. Briefly, ELISA was performed in 96-well plates (Costar, USA) coated with 0.5 \(\mu g\) of rSARS-CoV-2-S (KITGEN BIOTECHNOLOGY, China) per well in 100 \(\mu L\) bicarbonate buffer (pH 9.6). After being blocked with 5% FCS, 100 \(\mu L\) serum samples at several dilutions in PBS were added to the wells and incubated at 37°C for one hour. Then the HRP conjugated rabbit anti-goat IgG antibodies (1 : 3000, Solarbio, China) were added, and incubation continued at 37°C for one hour. The plate was developed using TMB (Solarbio, China), following 2 M \(H_2SO_4\) addition to stopping the reaction, and read at 450 nm by ELISA plate reader for final data. Samples were analyzed in duplicate.

**STATISTICAL ANALYSES**

Statistical analyses were performed with one-way ANOVA using GraphPad Prism 6.0. All data were expressed as the mean ± standard deviation.

**RESULTS**

**Construction of S. typhimurium Strains with phoP Mutation**

Given the ultimate objective of constructing a vaccine strain that would be safe in mammals, we generated a phoP strain by \(\lambda\)-Red recombination engineering using the one-step inactivation procedure developed by Datsenko and Wanner using pKD4-amplified PCR products. \(\lambda\)-Red functions were expressed from plasmid pKD46. Kanamycin cassettes were excised with the pCP20 plasmid as previously described (Figs. 1a, 1b) [16]. Strains were verified by genomic DNA PCR by using primers pair for the \(phoP\) gene or \(rpoD\) gene with RT-phoP-F&RT-phoP-R or RT-rpoD-F&RT-rpoD-R. PCR result indicate the \(phoP\) gene was removed from the chromosome site.

**Expression of the Recombinant Eukaryotic Expression Plasmid pcDNA3.1(+)-CMV-SARS-CoV-2-S-GFP in 293T Cells**

In order to investigate the ability of pcDNA3.1(+)-CMV-SARS-CoV-2-S-GFP to express the SARS-CoV-2-S protein, transfection, and western blot analysis were performed. A P2A ribosomal self-skipping sequence separates SARS-CoV-2-S from a GFP...
marker. The strong CMV promoter was driving SARS-CoV-2-S-GFP co-transcription and the P2A cleavage site separation of SARS-CoV-2-S and GFP during translation in eukaryotic cells [22]. The results demonstrated that 293T cells transfected with pcDNA3.1 (+)-CMV-SARS-CoV-2-S-GFP expressed the SARS-CoV-2-S protein compared with the cells transfected with the empty pcDNA3.1 (+)-CMV-GFP plasmid (Figs. 3a, 3b).

**Anti-SARS-CoV-2-S Protein Sera IgG Responses in the Rat after Orally Salmonella-Mediated DNA Vaccination**

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. Our animal protocols approved by the Animal Care and Use Committee, Office of Research Integrity and Assurance, Inner Mongolia International Mongolian Hospital. Rats (n = 9 per group) were orally immunized with ΔphoP strain with pSARS-CoV-2-S (1 × 10⁷ cfu/(doserat)), or ΔphoP strain with controls (plasmid) (Fig. 4). Rats were immunized on days 0, 7, and 14. Sera were collected on days 0, 14, and 28 days post-immunization (d.p.i). Estimate the antigen-specific humoral immune response after immunization with pSARS-CoV-2-S, antibody ELISA was performed on the sera collected from the rat immunized with pSARS-CoV-2-S or control plasmid. The pSARS-CoV-2-S vaccine elicited humoral immune response, as evidenced by the fold increased (pSARS-CoV-2-S group at 14 days, three rats of the nine rats increased to 4–5 times and another six rats increase to 8–9 times when compared with the control group. At 28 days, all rats increase to 4–6 times when compared with the control group, see Fig. 5) in the OD values between pSARS-CoV-2-S and control groups (None increase in all experiment period). This profile of IgG suggested that the novel consensus oral vaccine strategy used in this study elicited an antigen-specific IgG immune response (Fig. 5).

**DISCUSSION**

Various strategies have been explored to search for an effective vaccine against SARS-CoV-2, including the use of inactivated whole virus particles, attenuated live virus and gene vaccines [23–27]. Recently, the the gene vaccines that express SARS-CoV structural proteins and induce host immunity against SARS-CoV-2 have become increasingly popular.

Several bacterial species have been used to transfer eukaryotic expression plasmids into host cells. *Shigella flexneri*, *Listeria monocytogenes*, and recombinant *Escherichia coli* that harbor the invasion plasmid of Shigella have been used successfully [28–30]. Since these bacteria escape from the phagosome, it has been postulated that entry into the cytosol would be a crucial step in bacteria mediated transfection. Using attenuated strains of *S. flexneri* and *S. typhimurium* as
Fig. 4. The procedure of plasmid transformation to *Salmonella* strain and immunization of rat. Attenuated *Salmonella* carry with pSARS-CoV-2-S plasmid.

Fig. 5. Humoral responses to SARS-CoV-2-S protein antigen in the rat after immunization on day 0, day 14, and day 28 with *Salmonella* carrying the control vector or pSARS-CoV-2-S (as described in the methods). (A) After immunization with the control vector, test SARS-CoV-2-S protein antigen binding of IgG in serial serum dilutions from a rat at day (0, 14, 28). Data shown represent test mean OD 450 nm values (mean ± SD) for each of 9 rats, or (B) After immunization with the pSARS-CoV-2-S vector, SARS-CoV-2-S protein antigen binding of IgG in serial serum dilutions from a rat at day (0, 14, 28). Data shown represent mean OD 450 nm values (3 times measurement, mean ± SD) for each of 9 rats.
DNA carrier, antibody responses against the transgene could be detected in the animal model [12, 31].

Although oral administration of the vaccine is challenging, the socio-economic benefits of such vaccination are apparent. Moreover, oral vaccination could stimulate both humoral and cellular immune responses [32]. The most successful oral vaccine is the polio vaccine [33]. Our design of pSARS-CoV-2-S plasmid-based orally delivered vaccine was able to induce significant antigen-specific IgG antibodies. As indicated earlier, the COVID-19 protein SARS-CoV-2-S is considered a robust putative vaccine target due to it being significantly associated with the stimulation of SARS-CoV-2 [24]. This protein was found to be immunogenic and capable of eliciting an IgG response. Since the previous study developed a vaccine against MERS coronavirus; and other published studies of SARS vaccines, S protein was chosen as the antigen target [24, 25, 34]. The SARS-CoV-2 S protein is a class I membrane fusion protein, which the major envelope protein on the surface of coronaviruses. Initial studies have already been performed, which indicate antibodies can block SARS-CoV-2 interaction with its host receptor (ACE2) [35]. In vivo immunogenicity studies show the functional antibodies and T cell responses in multiple animal models after SARS-CoV-2-S expression plasmid or mRNA direct immunized to the animals or human [24, 25]. The administration of the SARS-CoV-2-S oral vaccine was found to induce the response. In the following study, the protection efficiency will be evaluated with a high dose of viral challenge in nonprimate mammals such as rhesus monkey.

CONCLUSIONS

In this investigation, we found that pSARS-CoV-2-S vaccine-elicited IgG immune response, as evidenced by the 0.5–1.2 fold increased after administration of pSARS-CoV-2-S from the beginning. These findings suggest attenuated Salmonella typhimurium carrying plasmid encoding SARS-CoV-2-S is one of the promising candidates for developing an oral delivery vaccine against SARS-CoV-2 infection in humans.

ACKNOWLEDGMENTS

The authors are grateful to Guojun Wang and Digengni for language revision. Dr. Morigen is acknowledged for share plasmid pKD4, pKD46, pCP20. Dr. Haisheng Yu is acknowledged for share plasmid pcDNA3.1(+)-CMV-SARS-CoV-2-S-GFP.

FUNDING

This study was supported by grants Novel Coronavirus prevention and control emergency project in 2020 of Inner Mongolia, China (Grant no. T101499.404), Inner Mongolia Plan of Science and Technology (Grant number: 2020GG0005).

COMPLIANCE WITH ETHICAL STANDARDS

Our study was approved by the Animal Care and Use Committee of Inner Mongolia International Mongolian Hospital and Sibeifu Biotechnology Company Limited (NO2020019001), China. All animal procedures were performed according to guidelines developed by the China Council on Animal Care and protocol approved by Animal Care and Use Committee of Inner Mongolia International Mongolian Hospital, China.

Conflict of Interest

The authors declare that they have no conflicts of interest.

CONSENT FOR PUBLICATION

Not applicable.

REFERENCES

1. El-Aziz, T.M.A. and Stockand, J.D., Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)—an update on the status, Infect., Genet. Evol., 2020, vol. 83, p. 104327.
2. Prompetchara, E., Ketloy, C., and Palaga, T., Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic, Asian Pac. J. Allergy Immunol., 2020, vol. 38, no. 1, pp. 1–9.
3. Callaway, E., The race for coronavirus vaccines: a graphical guide, Nature, 2020, vol. 580, no. 7805, pp. 576–577.
4. Corey, L., Mascola, J.R., Fau ci, A.S., and Collins, F.S., A strategic approach to COVID-19 vaccine R&D, Science, 2020, vol. 368, no. 6494, pp. 948–950.
5. Liu, R.-Y., Wu, L.-Z., Huang, B.-J., Huang, J.-L., Zhang, Y.-L., Ke, M.-L., Wang, J.-M., Tan, W.-P., Zhang, R.-H., Chen, H.-K., et al., Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats, Virus Res., 2005, vol. 112, no. 1, pp. 24–31.
6. Chan, J.F., Kok, K.H., Zhu, Z., Chu, H., To, K.K., Yuan, S., and Yuen, K.Y., Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerging Microbes Infect., 2020, vol. 9, no. 1, pp. 221–236.
7. Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al., Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China, Cell Host Microbe, 2020, vol. 27, no. 3, pp. 325–328.
8. Li, H., Liu, S.M., Yu, X.H., Tang, S.L., and Tang, C.K., Coronavirus disease 2019 (COVID-19): current status and future perspectives, Int. J. Antimicrob. Agents, 2020, vol. 55, no. 5, p. 105951.
9. Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al., Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains, Nat. Commun., 2017, vol. 8, p. 15092.
10. Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., Graham, B.S., and McElhaney, J.S., Cryo-EM structure of the 2019-nCoV spike in...
the prefuscation conformation, Science, 2020, vol. 367, no. 8483, pp. 1256–1263.

11. Klinman, D.M., Takeshita, F., Kamstrup, S., Takeshita, S., Ishii, K., Ichino, M., and Yamada, H., DNA vaccines: capacity to induce auto-immunity and tolerance, Dev. Biol. (Basel), 2000, vol. 104, pp. 45–51.

12. Darji, A., zur Lage, S., Garbe, A.I., Chakraborty, T., and Weiss, S., Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier, FEMS Immunol. Med. Microbiol., 2000, vol. 27, no. 4, pp. 341–349.

13. Lai, W.C. and Bennett, M., DNA vaccines, Crit. Rev. Immunol., 1998, vol. 18, no. 5, pp. 449–484.

14. Bukreyev, A., Lamirande, E.W., Buchholz, U.J., Vogel, L.N., Elkins, W.R., St. Claire, M., Murphy, B.R., Subbarao, K., and Collins, P.L., Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS, Lancet, 2004, vol. 363, no. 9427, pp. 2122–2127.

15. Gao, Q., Bao, L., Mao, H., Xu, K., Yang, M., and Weiss, S., Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial, Lancet, 2020, vol. 395, no. 10240, pp. 1845–1854.

16. van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J.N., Port, J.R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewskia, M., et al., ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques, Nature, 2020, vol. 586, pp. 578–582.